drugset / Trial / NCT03428594

CKD-11101 Phase 3 IV Study in Patients Who Had Renal Anemia Receiving Hemodialysis

NCT03428594

Phase 3 Completed 403 enrolled Chong Kun Dang Pharmaceutical
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The aim of this study was to compare and evaluate efficacy and safety of intravenous CKD-11101 versus Darbepoetin alfa in patients who have renal anemia receiving hemodialysis.

Timeline

Start
2015-06
Primary completion
2017-06
Completion
2017-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator Darbepoetin alfa Protein / enzyme biologic Intravenous
Comparator Darbepoetin alfa Protein / enzyme biologic